Market revenue in 2022 | USD 1,342.7 million |
Market revenue in 2030 | USD 8,538.1 million |
Growth rate | 26% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 62.56% in 2022. Horizon Databook has segmented the Asia Pacific cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is anticipated to be a growing market for cell and gene therapy manufacturing. The region accounted for a 26.0% revenue share in 2021 and is estimated to witness the fastest growth with a CAGR of 20.6% from 2021 to 2027.
Over the past several years, cell therapy market has gained momentum in Asia. This can be attributed to the establishment of accelerated approval pathways, growing private & government investments, and increasing healthcare needs.
Besides, unmet needs in personalized medicine are driving research for regenerative medicine technologies, in turn, leading to increase in demand for cell & gene therapy manufacturing services. Availability of funding grants, especially for cell & gene therapy manufacturing, is expected to further accelerate market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cell and gene therapy manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account